Cybin is trading 6.78% down at $13.07, with no clear company-specific announcement identified for September 18, 2026.
- Its September 16 Morgan Stanley presentation highlighted a first Phase 3 readout expected in the fourth quarter and upcoming trial-design details, but no apparent negative catalyst.
- The broader market is modestly lower, while biotech is higher, leaving the decline unexplained rather than sector-driven.